The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Model-Informed Recommended Phase 3 Dose for a novel KAT6 inhibitor, PF-07248144, Following Dose Optimization in 2L+ ER+/HER2- Metastatic Breast Cancer (mBC) population
Kowalski K, Liyanage M, Jermain B, Hahn E, Hee B, Pithavala Y, Li M, Masters J
Presentation
Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients with ER+/HER2− metastatic breast cancer: results from phase 1 study to support the recommended phase 3 dose
LoRusso P, Mukohara T, Sommerhalder D, Yonemori K, Hamilton E, Layman RM, Kim SB, Im SA, Rugo HS, Yamashita T, Yan F, Hara F, Kim G, Wang S, Kent S, Liu L, Skoura A, Kowalski K, Li M, Park YH
Poster
International phase 2 clinical trial comparing the effect of neoadjuvant PF-07220060 plus letrozole versus letrozole alone on Ki-67 tumor expression in postmenopausal women with HR+/HER2− breast cancer
Shom Goel, Khalil Zaman, Seock-Ah Im, Ahmed Elkhanany, Chiun-Sheng Huang, Cristian Villanueva, Sara Lopez Tarruella, Chin-Hee Chung, Ann Alcasid,Yuan Liu, ,Cynthia Basu, Michail Ignatiadis
Atirmociclib (PF-07220060) | December 13, 2024 | SABCS 2024
C4391025 | NCT06465368
Presentation
PHASE 1B/2 FIRST-IN-CLASS NOVEL COMBINATION TRIAL OF NEXT GENERATION CDK4-SELECTIVE INHIBITOR PF-07220060 AND NEXT GENERATION CDK2-SELECTIVE INHIBITOR PF-07104091 IN HR+ HER2- METASTATIC BREAST CANCER AND ADVANCED SOLID TUMORS
Yap T, Yan F, Sadeghi S, Lin T, Liu F, Malky L, Golmakani M, Moreau A, Neumann H, Zhou L, Juric D, Sharma M
Tegtociclib (PF-07104091) + Atirmociclib (PF-07220060) | September 13, 2024 | ESMO 2024
C4391002 | NCT05262400
Presentation
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor — PF-07248144 in patients with advanced or metastatic ER+ HER2− breast cancer
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Kim SB, Kim H, Iwata H, Yamashita T, Layman RM, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Mishra NH, Maity AK, Bogg O, Meng Li M, LoRusso PM